In March 2017 Accelerating Cancer Immunotherapy brought together cutting-edge researchers with frontline clinicians to accelerate knowledge in this fastest moving area of oncology. Operating across two auditoria, the faculty of globally recognised experts detailed their discoveries to a broad audience of healthcare professionals to enable better understanding of the likely upcoming treatment options for their patients.
Delegates from across the globe registered to attend the meeting, travelling from as far afield as Australia, India, the Americas and Europe.
The meeting was endorsed and supported by our colleagues at The Lancet and they hosted an exclusive session on Thursday morning Chaired by the Lancet Oncology Deputy Editor, Dr Cassandra Coburn. ACI was been awarded 11 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME)
Department Chair, Department of Immunology,
Division of Basic Science Research,
The University of Texas
MD Anderson Cancer Center,
Houston, TX, USA
|Professor Robert Schreiber, PhD
Alumni Professor, Pathology and Immunology;
Director, Center for Human Immunology and Immunotherapy Programs
St. Louis, MO. USA
ACI is supported by sponsorship from the Pharmaceutical Industry.
As support agreements are reached, disclosure of the supporters is listed here.